
ever since I was little I’ve been curious about how things work now most
curious about how things work now most
curious about how things work now most kids when they get a new toy they want
kids when they get a new toy they want
kids when they get a new toy they want to play with it but I always just wanted
to play with it but I always just wanted
to play with it but I always just wanted to take it apart but so you know I think
to take it apart but so you know I think
to take it apart but so you know I think that might have made my parents mad but
that might have made my parents mad but
that might have made my parents mad but they it signaled to them that I wanted
they it signaled to them that I wanted
they it signaled to them that I wanted to become a scientist which I did but I
to become a scientist which I did but I
to become a scientist which I did but I also had an event in high school
also had an event in high school
also had an event in high school happened to me that made me want to
happened to me that made me want to
happened to me that made me want to become a childhood cancer doctor and
become a childhood cancer doctor and
become a childhood cancer doctor and that was when my good friends younger
that was when my good friends younger
that was when my good friends younger brother this young boy Steven Daniel
brother this young boy Steven Daniel
brother this young boy Steven Daniel Jeffries was diagnosed with cancer
Jeffries was diagnosed with cancer
Jeffries was diagnosed with cancer Steven died at the age of 8 in 1975 in
Steven died at the age of 8 in 1975 in
Steven died at the age of 8 in 1975 in Columbia Maryland where I grew up from a
Columbia Maryland where I grew up from a
Columbia Maryland where I grew up from a rare type of pediatric cancer it was my
rare type of pediatric cancer it was my
rare type of pediatric cancer it was my first experience of what cancer can do
first experience of what cancer can do
first experience of what cancer can do to a person what cancer can do to a
to a person what cancer can do to a
to a person what cancer can do to a family to a community and I’ve learned a
family to a community and I’ve learned a
family to a community and I’ve learned a lot since then I’ve learned that well it
lot since then I’ve learned that well it
lot since then I’ve learned that well it took me 17 years of training to become a
took me 17 years of training to become a
took me 17 years of training to become a physician scientist and in the 20 plus
physician scientist and in the 20 plus
physician scientist and in the 20 plus years I’ve been practicing and seeing
years I’ve been practicing and seeing
years I’ve been practicing and seeing patients I’ve learned that there’s
patients I’ve learned that there’s
patients I’ve learned that there’s actually reason for hope there’s reason
actually reason for hope there’s reason
actually reason for hope there’s reason for hope because research cures cancer
for hope because research cures cancer
for hope because research cures cancer but we may need to rethink some of the
but we may need to rethink some of the
but we may need to rethink some of the things that we’ve been looking at in
things that we’ve been looking at in
things that we’ve been looking at in terms of developing the others let me
terms of developing the others let me
terms of developing the others let me explain so acute lymphoblastic leukemia
explain so acute lymphoblastic leukemia
explain so acute lymphoblastic leukemia or a ll is the most common type of
or a ll is the most common type of
or a ll is the most common type of cancer in children and this graph shows
cancer in children and this graph shows
cancer in children and this graph shows you the survival or the percentage of
you the survival or the percentage of
you the survival or the percentage of life of patients based on their years
life of patients based on their years
life of patients based on their years since diagnosis and in the year that I
since diagnosis and in the year that I
since diagnosis and in the year that I was Stevens aged 8 1968 the survival of
was Stevens aged 8 1968 the survival of
was Stevens aged 8 1968 the survival of patients with a ll was pretty bad so 50%
patients with a ll was pretty bad so 50%
patients with a ll was pretty bad so 50% of patients you can see from the dotted
of patients you can see from the dotted
of patients you can see from the dotted line only made it two years and only 10%
line only made it two years and only 10%
line only made it two years and only 10% of patients made it six years or more
of patients made it six years or more
of patients made it six years or more but through the careful application of
but through the careful application of
but through the careful application of research that is testing hypotheses this
research that is testing hypotheses this
research that is testing hypotheses this might work better than what we’re doing
might work better than what we’re doing
might work better than what we’re doing rejecting things that didn’t work and
rejecting things that didn’t work and
rejecting things that didn’t work and building on things that did work we were
building on things that did work we were
building on things that did work we were able to double that long term survival
able to double that long term survival
able to double that long term survival by the time I was 12 and we as a medical
by the time I was 12 and we as a medical
by the time I was 12 and we as a medical community continued to work on that
community continued to work on that
community continued to work on that and by the time I turned 17 patients
and by the time I turned 17 patients
and by the time I turned 17 patients diagnosed that year had a remarkable 60
diagnosed that year had a remarkable 60
diagnosed that year had a remarkable 60 percent cure rate we didn’t stop there
percent cure rate we didn’t stop there
percent cure rate we didn’t stop there however over the next several years and
however over the next several years and
however over the next several years and decades we continued to try new things
decades we continued to try new things
decades we continued to try new things as a community as scientists as medicine
as a community as scientists as medicine
as a community as scientists as medicine medical specialists until the year I
medical specialists until the year I
medical specialists until the year I turned 49 when ninety percent of
turned 49 when ninety percent of
turned 49 when ninety percent of patients were cured that’s the most
patients were cured that’s the most
patients were cured that’s the most recent year we have date data for
recent year we have date data for
recent year we have date data for because we have to follow them out five
because we have to follow them out five
because we have to follow them out five to ten years so we think today if you’re
to ten years so we think today if you’re
to ten years so we think today if you’re diagnosed with standard risk acute
diagnosed with standard risk acute
diagnosed with standard risk acute lymphoblastic leukemia of children in
lymphoblastic leukemia of children in
lymphoblastic leukemia of children in childhood you have over 95 percent
childhood you have over 95 percent
childhood you have over 95 percent survival that’s amazing
so my lesson is to trust research we
so my lesson is to trust research we trust science not only to figure out how
trust science not only to figure out how
trust science not only to figure out how things work which I love to do but also
things work which I love to do but also
things work which I love to do but also to make the world a better place to save
to make the world a better place to save
to make the world a better place to save lives but cancer remains the most common
lives but cancer remains the most common
lives but cancer remains the most common cause of death due to twosies and
cause of death due to twosies and
cause of death due to twosies and children so we need to have to have some
children so we need to have to have some
children so we need to have to have some more work to do what do we do about
more work to do what do we do about
more work to do what do we do about patients with advanced cancer like cake
patients with advanced cancer like cake
patients with advanced cancer like cake an 11 year old who came to me with this
an 11 year old who came to me with this
an 11 year old who came to me with this PET scan you can see the outline of her
PET scan you can see the outline of her
PET scan you can see the outline of her image and all the dark spots except what
image and all the dark spots except what
image and all the dark spots except what her bladder is which collects the tracer
her bladder is which collects the tracer
her bladder is which collects the tracer all the other spots are where her tumor
all the other spots are where her tumor
all the other spots are where her tumor spread she had a metastatic sarcoma this
spread she had a metastatic sarcoma this
spread she had a metastatic sarcoma this outcome for patients with metastatic
outcome for patients with metastatic
outcome for patients with metastatic solid tumors or other kinds of leukemias
solid tumors or other kinds of leukemias
solid tumors or other kinds of leukemias like acute myelogenous leukemia is still
like acute myelogenous leukemia is still
like acute myelogenous leukemia is still like a ll was in the 1960s again the
like a ll was in the 1960s again the
like a ll was in the 1960s again the survival based on the years of diagnosis
survival based on the years of diagnosis
survival based on the years of diagnosis and the survival for all patients pretty
and the survival for all patients pretty
and the survival for all patients pretty much with advanced cancer falls
much with advanced cancer falls
much with advanced cancer falls somewhere in this shaded range in 2017
somewhere in this shaded range in 2017
somewhere in this shaded range in 2017 why haven’t we done better well I submit
why haven’t we done better well I submit
why haven’t we done better well I submit to you that the strategy we’ve been
to you that the strategy we’ve been
to you that the strategy we’ve been using for developing drugs is somewhat
using for developing drugs is somewhat
using for developing drugs is somewhat flawed so in order to figure out how to
flawed so in order to figure out how to
flawed so in order to figure out how to do better we have to go back to the
do better we have to go back to the
do better we have to go back to the biology how does cancer work so we all
biology how does cancer work so we all
biology how does cancer work so we all know you’re probably learned in your
know you’re probably learned in your
know you’re probably learned in your high school biology class that the cell
high school biology class that the cell
high school biology class that the cell divides into and those two cells divide
divides into and those two cells divide
divides into and those two cells divide further and further until you get a
further and further until you get a
further and further until you get a massive cancer it’s usually a clonal
massive cancer it’s usually a clonal
massive cancer it’s usually a clonal population similar cells and at some
population similar cells and at some
population similar cells and at some point one of those cells breaks off and
point one of those cells breaks off and
point one of those cells breaks off and goes down the
goes down the
goes down the blood vessel or a lymph channel and
blood vessel or a lymph channel and
blood vessel or a lymph channel and finds another organ like the longer
finds another organ like the longer
finds another organ like the longer liver and starts dividing there that
liver and starts dividing there that
liver and starts dividing there that forms the metastasis like we saw in Kate
forms the metastasis like we saw in Kate
forms the metastasis like we saw in Kate and what we’ve done over the past
and what we’ve done over the past
and what we’ve done over the past several decades is take some of these
several decades is take some of these
several decades is take some of these tumor cells and grow them in a dish or
tumor cells and grow them in a dish or
tumor cells and grow them in a dish or put them in a mouse and test the drugs
put them in a mouse and test the drugs
put them in a mouse and test the drugs in the dish of the mouse and then only
in the dish of the mouse and then only
in the dish of the mouse and then only use those that work in the dish or a
use those that work in the dish or a
use those that work in the dish or a mouse and try them in people but we may
mouse and try them in people but we may
mouse and try them in people but we may be missing a lot with that simplistic
be missing a lot with that simplistic
be missing a lot with that simplistic view of the world we actually know a lot
view of the world we actually know a lot
view of the world we actually know a lot more about cancer than that so I did a
more about cancer than that so I did a
more about cancer than that so I did a keyword search of the word cancer in the
keyword search of the word cancer in the
keyword search of the word cancer in the world’s medical literature and I found
world’s medical literature and I found
world’s medical literature and I found that we’ve published over 3.5 million
that we’ve published over 3.5 million
that we’ve published over 3.5 million publications on cancer and just a
publications on cancer and just a
publications on cancer and just a hundred over 135,000 have been added
hundred over 135,000 have been added
hundred over 135,000 have been added this year alone so we know a lot now I
this year alone so we know a lot now I
this year alone so we know a lot now I haven’t read them all but I have tried
haven’t read them all but I have tried
haven’t read them all but I have tried to look at the literature to figure out
to look at the literature to figure out
to look at the literature to figure out what are some of the key features that
what are some of the key features that
what are some of the key features that we need to be looking at what might
we need to be looking at what might
we need to be looking at what might explain why we haven’t cured some of
explain why we haven’t cured some of
explain why we haven’t cured some of these other cancers and I boiled down to
these other cancers and I boiled down to
these other cancers and I boiled down to three key features and the first one is
three key features and the first one is
three key features and the first one is illustrated in this diagram so this is
illustrated in this diagram so this is
illustrated in this diagram so this is from a publication done by Lee ding and
from a publication done by Lee ding and
from a publication done by Lee ding and then Elaine Mardis Rick Wilson and both
then Elaine Mardis Rick Wilson and both
then Elaine Mardis Rick Wilson and both at Nationwide Children’s Hospital in
at Nationwide Children’s Hospital in
at Nationwide Children’s Hospital in Columbus Ohio and 36 others published a
Columbus Ohio and 36 others published a
Columbus Ohio and 36 others published a few years ago and they were able to
few years ago and they were able to
few years ago and they were able to genetically track individual cells in
genetically track individual cells in
genetically track individual cells in this case in a cute myelogenous leukemia
this case in a cute myelogenous leukemia
this case in a cute myelogenous leukemia patient you can see those cells on the
patient you can see those cells on the
patient you can see those cells on the left and they wear to track how those
left and they wear to track how those
left and they wear to track how those cells did over time and you can see in
cells did over time and you can see in
cells did over time and you can see in this particular patient that grey cell
this particular patient that grey cell
this particular patient that grey cell expanded to become the main dominant
expanded to become the main dominant
expanded to become the main dominant population in that person and then over
population in that person and then over
population in that person and then over time other cells appeared the orange one
time other cells appeared the orange one
time other cells appeared the orange one the pink one and with chemotherapy that
the pink one and with chemotherapy that
the pink one and with chemotherapy that composition changed most of those cells
composition changed most of those cells
composition changed most of those cells disappeared but some of them remained
disappeared but some of them remained
disappeared but some of them remained and then expanded further so later at
and then expanded further so later at
and then expanded further so later at relapse most of the cells are either
relapse most of the cells are either
relapse most of the cells are either orange or the pink with some of the grey
orange or the pink with some of the grey
orange or the pink with some of the grey now these are different cells that
now these are different cells that
now these are different cells that acquire mutations either genetically or
acquire mutations either genetically or
acquire mutations either genetically or epigenetically meaning changes in gene
epigenetically meaning changes in gene
epigenetically meaning changes in gene expression so I like to think of that as
expression so I like to think of that as
expression so I like to think of that as either their hardware their software has
either their hardware their software has
either their hardware their software has been corrupted from a normal cell so
been corrupted from a normal cell so
been corrupted from a normal cell so this gives diversity or heterogeneity
this gives diversity or heterogeneity
this gives diversity or heterogeneity within tumors so you don’t have just all
within tumors so you don’t have just all
within tumors so you don’t have just all that white all those white cells as you
that white all those white cells as you
that white all those white cells as you saw before the second thing is that
saw before the second thing is that
saw before the second thing is that tumors are not just comprised of tumor
tumors are not just comprised of tumor
tumors are not just comprised of tumor cells they actually have a lot of normal
cells they actually have a lot of normal
cells they actually have a lot of normal cells cancer is partner with normal
cells cancer is partner with normal
cells cancer is partner with normal cells they recruit them into their
cells they recruit them into their
cells they recruit them into their microenvironment and they’d cajole them
microenvironment and they’d cajole them
microenvironment and they’d cajole them into doing things for them normal cells
into doing things for them normal cells
into doing things for them normal cells produce substances that help tumors grow
produce substances that help tumors grow
produce substances that help tumors grow that help them resist therapy this is a
that help them resist therapy this is a
that help them resist therapy this is a image from a microscope of a tumor in my
image from a microscope of a tumor in my
image from a microscope of a tumor in my research laboratory where we could say
research laboratory where we could say
research laboratory where we could say stain the cells you can see all the blue
stain the cells you can see all the blue
stain the cells you can see all the blue cancer cells and then in there are brown
cancer cells and then in there are brown
cancer cells and then in there are brown cells and pink cells those are T cells
cells and pink cells those are T cells
cells and pink cells those are T cells of different types they may be in there
of different types they may be in there
of different types they may be in there suppressing immunity or they may be in
suppressing immunity or they may be in
suppressing immunity or they may be in there trying to fight off the cancer
there trying to fight off the cancer
there trying to fight off the cancer because T cells are part of the immune
because T cells are part of the immune
because T cells are part of the immune system we also know there’s a lot of
system we also know there’s a lot of
system we also know there’s a lot of other cells that are normal cells in
other cells that are normal cells in
other cells that are normal cells in them in a 200 macrophages other myeloid
them in a 200 macrophages other myeloid
them in a 200 macrophages other myeloid cells fibroblasts that help feed the
cells fibroblasts that help feed the
cells fibroblasts that help feed the tumor so when we put a cell in the dish
tumor so when we put a cell in the dish
tumor so when we put a cell in the dish and grow it those aren’t there and the
and grow it those aren’t there and the
and grow it those aren’t there and the third thing was an experiment that just
third thing was an experiment that just
third thing was an experiment that just blew me away when I saw it and this was
blew me away when I saw it and this was
blew me away when I saw it and this was done by Juan masa gay in New York a few
done by Juan masa gay in New York a few
done by Juan masa gay in New York a few years ago he stained a tumor green and a
years ago he stained a tumor green and a
years ago he stained a tumor green and a tumor red and implanted them on
tumor red and implanted them on
tumor red and implanted them on different sides of the mouse and after a
different sides of the mouse and after a
different sides of the mouse and after a few days extracted Zoomers looked at him
few days extracted Zoomers looked at him
few days extracted Zoomers looked at him under the microscope and each of them
under the microscope and each of them
under the microscope and each of them was a mixture of green and red so
was a mixture of green and red so
was a mixture of green and red so different sites of tumors are
different sites of tumors are
different sites of tumors are collaborating they’re communicating if
collaborating they’re communicating if
collaborating they’re communicating if one of those diversity corrupted cells
one of those diversity corrupted cells
one of those diversity corrupted cells gets it figures out how to make a better
gets it figures out how to make a better
gets it figures out how to make a better tumor it can pass that information along
tumor it can pass that information along
tumor it can pass that information along to all the other sites in modern-day
to all the other sites in modern-day
to all the other sites in modern-day words we’d probably call this collusion
so that gives us a different strategy a
so that gives us a different strategy a different picture of cancer that I’m not
different picture of cancer that I’m not
different picture of cancer that I’m not only for you now instead of just the two
only for you now instead of just the two
only for you now instead of just the two cells that are the same we know every
cells that are the same we know every
cells that are the same we know every time a cell divides they’re slightly
time a cell divides they’re slightly
time a cell divides they’re slightly different they acquire some corruption
different they acquire some corruption
different they acquire some corruption of their software or their hardware they
of their software or their hardware they
of their software or their hardware they evolve they change and they continue to
evolve they change and they continue to
evolve they change and they continue to do that as they divide and divide so you
do that as they divide and divide so you
do that as they divide and divide so you get a heterogeneous mass that some cells
get a heterogeneous mass that some cells
get a heterogeneous mass that some cells made of I respond to your treatment but
made of I respond to your treatment but
made of I respond to your treatment but some may not and we know that when these
some may not and we know that when these
some may not and we know that when these cells break off and go down their blood
cells break off and go down their blood
cells break off and go down their blood vessel like we saw before and go into a
vessel like we saw before and go into a
vessel like we saw before and go into a different organ those cells start
different organ those cells start
different organ those cells start dividing in that other organ and in that
dividing in that other organ and in that
dividing in that other organ and in that metastatic site they’re evolving they’re
metastatic site they’re evolving they’re
metastatic site they’re evolving they’re changing so what’s in that metastatic
changing so what’s in that metastatic
changing so what’s in that metastatic site is different from what’s in that
site is different from what’s in that
site is different from what’s in that primary site and probably different from
primary site and probably different from
primary site and probably different from all the other metastatic sites and when
all the other metastatic sites and when
all the other metastatic sites and when we take one of those cells and put it in
we take one of those cells and put it in
we take one of those cells and put it in a dish and grow it it continues to
a dish and grow it it continues to
a dish and grow it it continues to evolve it’s now adapting to growth in a
evolve it’s now adapting to growth in a
evolve it’s now adapting to growth in a dish so it changes it’s no longer the
dish so it changes it’s no longer the
dish so it changes it’s no longer the same as what it wasn’t that person if we
same as what it wasn’t that person if we
same as what it wasn’t that person if we put it in a mouse same thing it’s
put it in a mouse same thing it’s
put it in a mouse same thing it’s different so when we’re testing drugs in
different so when we’re testing drugs in
different so when we’re testing drugs in the dish of the mouse without the
the dish of the mouse without the
the dish of the mouse without the presence of normal cells without the
presence of normal cells without the
presence of normal cells without the collusion between different sites where
collusion between different sites where
collusion between different sites where might be kidding ourselves and missing a
might be kidding ourselves and missing a
might be kidding ourselves and missing a lot
lot
lot now these tumor cells when their this
now these tumor cells when their this
now these tumor cells when their this difference should be recognized by the
difference should be recognized by the
difference should be recognized by the immune system which are these blue cells
immune system which are these blue cells
immune system which are these blue cells these T cells coming in from the
these T cells coming in from the
these T cells coming in from the vasculature that normally kill or
vasculature that normally kill or
vasculature that normally kill or destroy infected tissue or tissue that
destroy infected tissue or tissue that
destroy infected tissue or tissue that shouldn’t be there foreign tissue that’s
shouldn’t be there foreign tissue that’s
shouldn’t be there foreign tissue that’s what rejection of organs is and they
what rejection of organs is and they
what rejection of organs is and they should be rejecting the tumor and we see
should be rejecting the tumor and we see
should be rejecting the tumor and we see T cells in the slide like I showed you
T cells in the slide like I showed you
T cells in the slide like I showed you but they’re not doing anything they’re
but they’re not doing anything they’re
but they’re not doing anything they’re inert they’re just they’re put asleep
inert they’re just they’re put asleep
inert they’re just they’re put asleep they’re suppressed and we now know why
they’re suppressed and we now know why
they’re suppressed and we now know why that is we didn’t understand this for
that is we didn’t understand this for
that is we didn’t understand this for many many years but it’s those normal
many many years but it’s those normal
many many years but it’s those normal cells in many cases that are coming into
cells in many cases that are coming into
cells in many cases that are coming into the tumor and they’re producing
the tumor and they’re producing
the tumor and they’re producing substances tgf-beta il-10 PDL one these
substances tgf-beta il-10 PDL one these
substances tgf-beta il-10 PDL one these are molecules that suppress the immune
are molecules that suppress the immune
are molecules that suppress the immune response and don’t allow these T cells
response and don’t allow these T cells
response and don’t allow these T cells to reject the tumor so we need to think
to reject the tumor so we need to think
to reject the tumor so we need to think about that and then finally the
about that and then finally the
about that and then finally the collusion I talked about these tumor
collusion I talked about these tumor
collusion I talked about these tumor sites are exchanging information they’re
sites are exchanging information they’re
sites are exchanging information they’re not only trading tumor cells those red
not only trading tumor cells those red
not only trading tumor cells those red and green cells they’re trading some of
and green cells they’re trading some of
and green cells they’re trading some of these normal cells have been adapted or
these normal cells have been adapted or
these normal cells have been adapted or coerced to do the tumors bidding they’re
coerced to do the tumors bidding they’re
coerced to do the tumors bidding they’re trading those normally those substances
trading those normally those substances
trading those normally those substances that are suppressing immunity
that are suppressing immunity
that are suppressing immunity and it’s a real big conspiracy against
and it’s a real big conspiracy against
and it’s a real big conspiracy against us it cancer metastatic cancer is like
us it cancer metastatic cancer is like
us it cancer metastatic cancer is like an organism living within us conspiring
an organism living within us conspiring
an organism living within us conspiring against us so we need to think about
against us so we need to think about
against us so we need to think about these three features of cancer if we are
these three features of cancer if we are
these three features of cancer if we are going to make progress against advanced
going to make progress against advanced
going to make progress against advanced cancer the corruption of the genetics
cancer the corruption of the genetics
cancer the corruption of the genetics the diversity the coercion of normal
the diversity the coercion of normal
the diversity the coercion of normal cells which aren’t present in a dish and
cells which aren’t present in a dish and
cells which aren’t present in a dish and the collusion between sites that are
the collusion between sites that are
the collusion between sites that are feeding each other and helping each
feeding each other and helping each
feeding each other and helping each other so I challenge the medical
other so I challenge the medical
other so I challenge the medical community whether you’re in the
community whether you’re in the
community whether you’re in the pharmaceutical industry a cancer
pharmaceutical industry a cancer
pharmaceutical industry a cancer scientist whether you’re an advocate
scientist whether you’re an advocate
scientist whether you’re an advocate who’s raising money from projects and
who’s raising money from projects and
who’s raising money from projects and supporting research which we thank you
supporting research which we thank you
supporting research which we thank you ask yourselves is what I’m doing or what
ask yourselves is what I’m doing or what
ask yourselves is what I’m doing or what I supporting addressing at least one if
I supporting addressing at least one if
I supporting addressing at least one if not all three of these features of
not all three of these features of
not all three of these features of cancer because these are gonna what
cancer because these are gonna what
cancer because these are gonna what what’s going to take us to the next
what’s going to take us to the next
what’s going to take us to the next level to cure advanced cancer corruption
level to cure advanced cancer corruption
level to cure advanced cancer corruption coercion and collusion definitely
coercion and collusion definitely
coercion and collusion definitely something since CNN should be interested
something since CNN should be interested
something since CNN should be interested in now what we’re doing in my research
in now what we’re doing in my research
in now what we’re doing in my research laboratory at Nationwide Children’s
laboratory at Nationwide Children’s
laboratory at Nationwide Children’s Hospital here in Columbus is we’re
Hospital here in Columbus is we’re
Hospital here in Columbus is we’re injecting these tumors with live viruses
injecting these tumors with live viruses
injecting these tumors with live viruses the viruses are attenuated meaning
the viruses are attenuated meaning
the viruses are attenuated meaning they’re crippled they don’t cause
they’re crippled they don’t cause
they’re crippled they don’t cause disease they can still infect and kill
disease they can still infect and kill
disease they can still infect and kill some of those tumor cells and we’re
some of those tumor cells and we’re
some of those tumor cells and we’re combining these and that that tricks the
combining these and that that tricks the
combining these and that that tricks the cancer into thinking in the immune
cancer into thinking in the immune
cancer into thinking in the immune system into thinking cancers an
system into thinking cancers an
system into thinking cancers an infection and brings in all those
infection and brings in all those
infection and brings in all those t-cells and when we combine it with
t-cells and when we combine it with
t-cells and when we combine it with drugs that target some of those normal
drugs that target some of those normal
drugs that target some of those normal substances those normal cells we can lay
substances those normal cells we can lay
substances those normal cells we can lay the cancer bare and get some really good
the cancer bare and get some really good
the cancer bare and get some really good shrinkage results and we’re hoping to
shrinkage results and we’re hoping to
shrinkage results and we’re hoping to achieve the same sort of thing in people
achieve the same sort of thing in people
achieve the same sort of thing in people but there’s probably many other ways
but there’s probably many other ways
but there’s probably many other ways that we as a scientific community can
that we as a scientific community can
that we as a scientific community can think about how to address those three
think about how to address those three
think about how to address those three C’s as you can imagine it takes time as
C’s as you can imagine it takes time as
C’s as you can imagine it takes time as you saw several decades to make real
you saw several decades to make real
you saw several decades to make real progress with a ll and it takes money so
progress with a ll and it takes money so
progress with a ll and it takes money so I thought I’d just check in with our
I thought I’d just check in with our
I thought I’d just check in with our National Priorities since it was just
National Priorities since it was just
National Priorities since it was just Halloween we spent over eight billion
Halloween we spent over eight billion
Halloween we spent over eight billion dollars with Abby on Halloween candy
dollars with Abby on Halloween candy
dollars with Abby on Halloween candy which is three billion more than the
which is three billion more than the
which is three billion more than the entire budget of the National Cancer
entire budget of the National Cancer
entire budget of the National Cancer Institute and the National Cancer
Institute and the National Cancer
Institute and the National Cancer Institute is the largest funder public
Institute is the largest funder public
Institute is the largest funder public funder of cancer research in the world
funder of cancer research in the world
funder of cancer research in the world we spent about half that amount on hot
we spent about half that amount on hot
we spent about half that amount on hot dogs each year and point eight billion
dogs each year and point eight billion
dogs each year and point eight billion dollars on July 4th fireworks which is
dollars on July 4th fireworks which is
dollars on July 4th fireworks which is four times the amount the National
four times the amount the National
four times the amount the National Cancer spends
Cancer spends
Cancer spends on children only 4% of the National
on children only 4% of the National
on children only 4% of the National Cancer Institute’s budget goes to
Cancer Institute’s budget goes to
Cancer Institute’s budget goes to children I had the privilege of spending
children I had the privilege of spending
children I had the privilege of spending some time in Washington DC at a
some time in Washington DC at a
some time in Washington DC at a candlelight vigil about two months ago
it was quite a moving experience not
it was quite a moving experience not only were we paying tribute and in
only were we paying tribute and in
only were we paying tribute and in memory of those we lost but we were
memory of those we lost but we were
memory of those we lost but we were trying to raise awareness about cancer
trying to raise awareness about cancer
trying to raise awareness about cancer research and about funding and these are
research and about funding and these are
research and about funding and these are people who know the power of research
people who know the power of research
people who know the power of research because these are people who know the
because these are people who know the
because these are people who know the story about a o/l through research we’ve
story about a o/l through research we’ve
story about a o/l through research we’ve been able to cure áall cancer let’s not
been able to cure áall cancer let’s not
been able to cure áall cancer let’s not stop until we cure all cancer thank you
stop until we cure all cancer thank you
stop until we cure all cancer thank you [Applause]
”
Be First to Comment